$15.99 Million in Sales Expected for Esperion Therapeutics, Inc. (NASDAQ:ESPR) This Quarter

Wall Street analysts expect Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Rating) to post sales of $15.99 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Esperion Therapeutics’ earnings. The highest sales estimate is $17.48 million and the lowest is $14.50 million. Esperion Therapeutics reported sales of $7.98 million in the same quarter last year, which would suggest a positive year over year growth rate of 100.4%. The company is scheduled to report its next earnings results on Monday, January 1st.

On average, analysts expect that Esperion Therapeutics will report full-year sales of $79.49 million for the current year, with estimates ranging from $73.20 million to $88.10 million. For the next financial year, analysts anticipate that the firm will report sales of $175.36 million, with estimates ranging from $111.60 million to $286.91 million. Zacks’ sales averages are an average based on a survey of sell-side research analysts that cover Esperion Therapeutics.

Esperion Therapeutics (NASDAQ:ESPR – Get Rating) last issued its quarterly earnings results on Tuesday, February 22nd. The biopharmaceutical company reported ($1.77) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.32) by $0.55. The business had revenue of $15.40 million for the quarter, compared to analyst estimates of $14.48 million. The business’s revenue for the quarter was up 60.4% on a year-over-year basis. During the same period in the previous year, the company posted ($3.89) earnings per share.

ESPR has been the topic of several research reports. HC Wainwright initiated coverage on Esperion Therapeutics in a research report on Thursday, March 10th. They issued a “buy” rating and a $22.00 target price on the stock. Credit Suisse Group cut their target price on Esperion Therapeutics from $8.00 to $6.00 and set a “neutral” rating on the stock in a research report on Friday, January 14th. StockNews.com initiated coverage on Esperion Therapeutics in a research report on Thursday, March 31st. They issued a “sell” rating on the stock. Finally, Northland Securities cut their target price on Esperion Therapeutics from $10.00 to $5.00 in a research report on Wednesday, January 12th. Three research analysts have rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Esperion Therapeutics has a consensus rating of “Hold” and a consensus price target of $27.50.

Institutional investors and hedge funds have recently made changes to their positions in the business. ProShare Advisors LLC acquired a new stake in Esperion Therapeutics during the 4th quarter worth about $50,000. Spire Wealth Management purchased a new stake in shares of Esperion Therapeutics during the 4th quarter worth about $51,000. National Bank of Canada FI purchased a new stake in shares of Esperion Therapeutics during the 4th quarter worth about $61,000. Citigroup Inc. boosted its stake in shares of Esperion Therapeutics by 187.9% during the 4th quarter. Citigroup Inc. now owns 14,641 shares of the biopharmaceutical company’s stock worth $73,000 after acquiring an additional 9,556 shares in the last quarter. Finally, Wells Fargo & Company MN boosted its stake in shares of Esperion Therapeutics by 461.0% during the 4th quarter. Wells Fargo & Company MN now owns 14,760 shares of the biopharmaceutical company’s stock worth $74,000 after acquiring an additional 12,129 shares in the last quarter.

Shares of ESPR stock opened at $5.03 on Tuesday. The business’s fifty day simple moving average is $4.72 and its 200-day simple moving average is $6.08. The company has a market cap of $315.99 million, a PE ratio of -0.53 and a beta of 0.66. Esperion Therapeutics has a 12-month low of $3.28 and a 12-month high of $28.78.

Esperion Therapeutics Company Profile (Get Rating)

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol. Its lead product candidates are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets for the treatment of patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia.

Read More